A Phase 3 interventional study of insulin degludec/insulin aspart and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 51 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-02.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 32nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 274 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 183rd largest by enrollment of the 428 interventional ones that give a count, is one of 33 that started in 2013, is one of 187 in phase 3, and was the 328th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Europe and the United States of America (USA).
The aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp) and/or oral anti-diabetic drugs (OADs) and insulin degludec (IDeg) plus insulin aspart (IAsp)and/or OADs.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 274 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart
Drug: insulin degludec · Drug: insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
Change From Baseline in HbA1c (%)
Change from baseline in HbA1c (%) after 26 weeks of treatment
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in FPG after 26 weeks of treatment
Time frame: Week 0, week 26
Number of Treatment Emergent Hypoglycaemic Episodes
According to the Novo Nordisk definition for confirmed hypoglycaemic episodes (severe hypoglycaemia and/or a measured Plasma Glucose (PG) \<3.1 mmol/L(56 mg/dL))
Time frame: During Weeks 0-26
Number of Treatment Emergent Hypoglycaemic Episodes
According to the American Diabetes Association (ADA) definition following are the categories of hypoglycaemic episodes: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Relative hypoglycaemia
Time frame: During Weeks 0-26
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes
Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
Time frame: Weeks 0-26
Incidence of Treatment Emergent Adverse Events (TEAE)
A TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment
Time frame: Weeks 0-26
The trial was conducted in 5 countries (48 sites): Algeria (4), Austria (6), France (8), Norway (6) and United States (24).
| Milestone | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Started | 138 | 136 |
| Exposed | 136 | 135 |
| Completed | 113 | 117 |
| Not completed | 25 | 19 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Withdrawal criteria | 21 | 12 |
| Withdrew: Unclassified | 4 | 2 |
Change from baseline in HbA1c (%) after 26 weeks of treatment
| percentage change in HbA1c | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Change From Baseline in HbA1c (%) | -1.23 ± 0.13 | -1.42 ± 0.12 |
Change from baseline in FPG after 26 weeks of treatment
| mmol/L | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -2.22 ± 0.38 | -1.90 ± 0.36 |
According to the Novo Nordisk definition for confirmed hypoglycaemic episodes (severe hypoglycaemia and/or a measured Plasma Glucose (PG) \<3.1 mmol/L(56 mg/dL))
| episodes | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes | 706 | 841 |
According to the American Diabetes Association (ADA) definition following are the categories of hypoglycaemic episodes: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Relative hypoglycaemia
| episodes | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| ADA (American Diabetes Association) | 2894 | 2685 |
| Severe | 29 | 15 |
| Documented symptomatic | 1818 | 1843 |
| Asymptomatic | 930 | 728 |
| Probable symptomatic | 26 | 33 |
| Relative | 91 | 66 |
Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
| episodes | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes | 75 | 96 |
A TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment
| number of events | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAE) | 330 | 298 |
Collected over The adverse events (AEs) were collected for a duration of 28 weeks ie. from the first trial-related activity after the subject had signed the informed consent until the end of the post-treatment follow-up period (visit 29).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegAsp BID | — | 7/136 (5.1%) | 46/136 (33.8%) |
| IDeg OD+IAsp | — | 13/135 (9.6%) | 38/135 (28.1%) |
| Event | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/136 | 2/135 |
| Wrong drug administeredInjury, poisoning and procedural complications | 0/136 | 2/135 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/136 | 2/135 |
| Ocular hypertensionEye disorders | 0/136 | 1/135 |
| Rib fractureInjury, poisoning and procedural complications | 0/136 | 1/135 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/136 | 1/135 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/136 | 1/135 |
| Hypoglycaemic unconsciousnessNervous system disorders | 1/136 | 1/135 |
| DepressionPsychiatric disorders | 0/136 | 1/135 |
| Suicidal ideationPsychiatric disorders | 0/136 | 1/135 |
| Event | IDegAsp BID | IDeg OD+IAsp |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/136 | 12/135 |
| AstheniaGeneral disorders | 10/136 | 2/135 |
| HeadacheNervous system disorders | 10/136 | 8/135 |
| DiarrhoeaGastrointestinal disorders | 9/136 | 9/135 |
| InfluenzaInfections and infestations | 9/136 | 5/135 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/136 | 3/135 |
| Back painMusculoskeletal and connective tissue disorders | 5/136 | 7/135 |
| FatigueGeneral disorders | 7/136 | 1/135 |
The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised".
| Age, Continuous(years) | IDegAsp BID | IDeg OD+IAsp | Total |
|---|---|---|---|
| Age | 59.6 ± 8.3 | 59.6 ± 9.2 | 59.6 ± 8.7 |
| Sex: Female, Male(Participants) | IDegAsp BID | IDeg OD+IAsp | Total |
|---|---|---|---|
| Female | 65 | 50 | 115 |
| Male | 73 | 86 | 159 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDegAsp BID | IDeg OD+IAsp | Total |
|---|---|---|---|
| Mean | 8.3 ± 0.9 | 8.3 ± 0.7 | 8.3 ± 0.8 |
| Fasting plasma glucose(mmol/L) | IDegAsp BID | IDeg OD+IAsp | Total |
|---|---|---|---|
| Mean | 9.0 ± 3.0 | 8.8 ± 2.9 | 8.9 ± 3.0 |
Ran from Feb 2013 to primary completion in Jan 2014, 10 months.
Results were first posted in Nov 2015, 1 year 10 months after primary completion. A results delay was requested in Jan 2014.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart